TY - JOUR
T1 - Analyzing tumor heterogeneity and driver genes in single myeloid leukemia cells with SBCapSeq
AU - Mann, Karen M.
AU - Newberg, Justin Y.
AU - Black, Michael A.
AU - Jones, Devin J.
AU - Amaya-Manzanares, Felipe
AU - Guzman-Rojas, Liliana
AU - Kodama, Takahiro
AU - Ward, Jerrold M.
AU - Rust, Alistair G.
AU - Van Der Weyden, Louise
AU - Yew, Christopher Chin Kuan
AU - Waters, Jill L.
AU - Leung, Marco L.
AU - Rogers, Keith
AU - Rogers, Susan M.
AU - Mcnoe, Leslie A.
AU - Selvanesan, Luxmanan
AU - Navin, Nicholas
AU - Jenkins, Nancy A.
AU - Copeland, Neal G.
AU - Mann, Michael B.
N1 - Publisher Copyright:
© 2016 Nature America, Inc. All rights reserved.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - A central challenge in oncology is how to kill tumors containing heterogeneous cell populations defined by different combinations of mutated genes. Identifying these mutated genes and understanding how they cooperate requires single-cell analysis, but current single-cell analytic methods, such as PCR-based strategies or whole-exome sequencing, are biased, lack sequencing depth or are cost prohibitive. Transposon-based mutagenesis allows the identification of early cancer drivers, but current sequencing methods have limitations that prevent single-cell analysis. We report a liquid-phase, capture-based sequencing and bioinformatics pipeline, Sleeping Beauty (SB) capture hybridization sequencing (SBCapSeq), that facilitates sequencing of transposon insertion sites from single tumor cells in a SB mouse model of myeloid leukemia (ML). SBCapSeq analysis of just 26 cells from one tumor revealed the tumor's major clonal subpopulations, enabled detection of clonal insertion events not detected by other sequencing methods and led to the identification of dominant subclones, each containing a unique pair of interacting gene drivers along with three to six cooperating cancer genes with SB-driven expression changes.
AB - A central challenge in oncology is how to kill tumors containing heterogeneous cell populations defined by different combinations of mutated genes. Identifying these mutated genes and understanding how they cooperate requires single-cell analysis, but current single-cell analytic methods, such as PCR-based strategies or whole-exome sequencing, are biased, lack sequencing depth or are cost prohibitive. Transposon-based mutagenesis allows the identification of early cancer drivers, but current sequencing methods have limitations that prevent single-cell analysis. We report a liquid-phase, capture-based sequencing and bioinformatics pipeline, Sleeping Beauty (SB) capture hybridization sequencing (SBCapSeq), that facilitates sequencing of transposon insertion sites from single tumor cells in a SB mouse model of myeloid leukemia (ML). SBCapSeq analysis of just 26 cells from one tumor revealed the tumor's major clonal subpopulations, enabled detection of clonal insertion events not detected by other sequencing methods and led to the identification of dominant subclones, each containing a unique pair of interacting gene drivers along with three to six cooperating cancer genes with SB-driven expression changes.
UR - http://www.scopus.com/inward/record.url?scp=84987657154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987657154&partnerID=8YFLogxK
U2 - 10.1038/nbt.3637
DO - 10.1038/nbt.3637
M3 - Article
C2 - 27479497
AN - SCOPUS:84987657154
SN - 1087-0156
VL - 34
SP - 962
EP - 972
JO - Nature Biotechnology
JF - Nature Biotechnology
IS - 9
ER -